N
Google TrendJONAS BROTHERS (500+) — Jonas Brothers postpone Birmingham concert over weather concerns
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:jonas brothers500+steven kwan500+kings vs warriors200+steffi graf200+boxing200+ben simmons500+lisa500+bill maher500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "BCMA/GPRC5D CAR T-Cell Th" (30 stories)

Top Headline Story

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma
Lead StoryNaturegeneral
4d ago

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1xdmlXeU51eS12YVpZR0M0eWlpSnliMTVDV0VtemNVdEtUUnd2X1pIaXc4d3plWXNLb244aUpXek1jMUhZdlJpTGVTdHpjOFU1MUVkNWVrNHU0UE5XVUQ0?oc=5" target="_blank">Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+21m ago

jonas brothers

Jonas Brothers postpone Birmingham concert over weather concerns

Filter stories
500+21m ago

steven kwan

Guardians' Steven Kwan Could Shake Up Winter Outfield Market

Filter stories
200+21m ago

kings vs warriors

3 Storylines I'm Focused On in Warriors Preseason Game vs. Kings

Filter stories
200+21m ago

steffi graf

PICTURES: Steffi Graf & Daughter Jaz Feature In Andre Agassi’s ‘Photo Dump’ As Carlos Alcaraz & Karl-Anthony Towns Make Surprise Appearance

Filter stories

Search Results for "BCMA/GPRC5D CAR T-Cell Th"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
CancerNetworkgeneral

BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOQmJ4NmYwSWU5NGtWalJ4d2o0U1VPc0F2TUVYaWVYUDBrdHpZZjh4TTdlUnRsRjhiN044RXN4bl9kMGdDNkVtSHBqTGw2RnNZb2JMb3FNT2xCUnJvb0h6d1Y0czFzT0NvTVNpU3F4MElDaXR3QlNsMFo5THhzQ3lEMkNBWUhEYlRxSVB1a0FDa0VhRS1mOE80N1NpWXZsU2dQSzZENFFSY2M3aktJUG5j?oc=5" target="_blank">BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Novel GPRC5D-Directed CAR T-Cell Therapy Produces Durable Remissions in R/R Myeloma
OncLivegeneral

Novel GPRC5D-Directed CAR T-Cell Therapy Produces Durable Remissions in R/R Myeloma

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNQVlocDBKVldQdnN1MGExSERWSldJNTJSSXJyWGJaVWlEN05ncllfZFRGakY0Z2MwREJMb1pFbDNkLVRwQk1kZ2hJQ3ZEcEpLMDZWTTE3aFRRNUFvS1Jfa1FNWjlzTXJ2eGhDNFhrWG5xRGhiQ3puN01xVk1CNVZYX0gtYzlNek0zZnNiYVFzalhybi1GVHpIN0hKdzBaS05UdWp5ZVotN1FzT1JzaU1ZZWh3?oc=5" target="_blank">Novel GPRC5D-Directed CAR T-Cell Therapy Produces Durable Remissions in R/R Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
IASO Bio’s BCMA/GPRC5D dual-targeted CAR-T RD140 shows 88.9% response rate in Phase I
AllScigeneral

IASO Bio’s BCMA/GPRC5D dual-targeted CAR-T RD140 shows 88.9% response rate in Phase I

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxQZGtmTGRFY21SQ1hMYTJaNm82UWpuR0FsOWJmZzRCUjUtOWNXTzF2RVE4dnVpc2hEbS1VdjB6eVVCVlNiVEpFUHlUQk55Qi1zZzJJMzgxY1dmMkJYTkl2QmRpNXk0cWZwYktJOW1vVnYtWWRjOE1BZFQ3amdXdVhjUlRGQ1V3dw?oc=5" target="_blank">IASO Bio’s BCMA/GPRC5D dual-targeted CAR-T RD140 shows 88.9% response rate in Phase I</a>  <font color="#6f6f6f">AllSci</font>

Read Full StoryMore like this
BMS’ pivotal CAR-T multiple myeloma trial hits primary endpoint
Fierce Biotechgeneral

BMS’ pivotal CAR-T multiple myeloma trial hits primary endpoint

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPNVQzak9pWHdSSVlpbHEyc29FczdmQUVmQjZ4OF96cHRWcEZQbDlGOEVHbElrNENXQW5iQTZKSEdBWVpvNU9zSFhaclR6b0xSUzVIQWFydDhWU3d1WTlaSk5ZcUZPRU9PS2lIa1BDS1JvT21BVnFJaFl3R2VQSVlCZ2VkZHBfdl8tN1lWTFNZZ3RfYUc0VDE0eEtaOFBKOFg4Sm1qOVE5MlRTMG5RNF9Z?oc=5" target="_blank">BMS’ pivotal CAR-T multiple myeloma trial hits primary endpoint</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
T-Cell–Redirecting Therapy With Bispecific Antibodies in Relapsed/Refractory Myeloma: Examining Use in Earlier Lines
ASCO Daily Newsgeneral

T-Cell–Redirecting Therapy With Bispecific Antibodies in Relapsed/Refractory Myeloma: Examining Use in Earlier Lines

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQcnFVaHZXOExWZkFKTW9pSE55RHltTHZIS1FUY0pKTGMtY3pkM2psenRFOFFvbkhmZDRCTEMzMHpCRzFfVHhibHdWZXE2ZHhUbXNkcmlmRlpEZW11dkJtRGltMHJCR0p2NUsyS1NOdzNuVkd6emh4ajdXNnM3RHNpTmRuYUJGQkJCTEppeTE3U3BDMF9xY2ctVFliZXBoWExPQ3NBYUt4bk1OU09uUE55dGktTHl4T0w0VVpfUw?oc=5" target="_blank">T-Cell–Redirecting Therapy With Bispecific Antibodies in Relapsed/Refractory Myeloma: Examining Use in Earlier Lines</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review | Legiec | Acta Haematologica Polonica
Via Medica Journalsgeneral

Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review | Legiec | Acta Haematologica Polonica

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPQVhyVXNDT2ZPaS12Y0lDM1gyck45MU50aE4yenJGbjJmaWVidm9oSEJTdTlzd2puVUV4UHpDMHpKTF9JeXpnNkdDaUV5Y3BiVHIyUkF4R1pvOG1ySkRYTE9PRzd3Ynp3aUNPaE5BX2hDQ2NpMFVzemZ6MUsyTTBJUjRqZw?oc=5" target="_blank">Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review | Legiec | Acta Haematologica Polonica</a>  <font color="#6f6f6f">Via Medica Journals</font>

Read Full StoryMore like this
Tempest Therapeutics Announces Exclusive Option Agreement with Senlang for CD7-Targeted Lentiviral In Vivo CAR-T Platform and BCMA/GPRC5D Candidate
Quiver Quantitativeworld

Tempest Therapeutics Announces Exclusive Option Agreement with Senlang for CD7-Targeted Lentiviral In Vivo CAR-T Platform and BCMA/GPRC5D Candidate

<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxNUlNSeUJfVnpJWF9fNlZ1MVRzRURRdkZaVVluNTU1TURucUxtbC16SXdESEIzZmRmOV9NUGZicVI1elRHRWx4MlJkd3BsM25pMVhpaW5ZUC1jdjVCTllCaWUyQ3NzOW9JUEJPT2VZNk5CMTY2RS10OHdqU0dFM2NTVW9vX19pTDBCVzViTGJaZ1lOUDhEWGJINlUxRjNqVEVUWDNyXzVIVmJ3TFd5NmpqZ2llc3ZJYmZoZzd1dGo3YlVfRmFmRFlrbVJrVmRGT0JGSE9yZ3hFRkN1X2VlejNsdmwwRTZzRkNuWHlKdjNBQm9hUzBYRjE0aXo1a0NHdThsMjZORE1KZ2tGNGdK?oc=5" target="_blank">Tempest Therapeutics Announces Exclusive Option Agreement with Senlang for CD7-Targeted Lentiviral In Vivo CAR-T Platform and BCMA/GPRC5D Candidate</a>  <font color="#6f6f6f">Quiver Quantitative</font>

Read Full StoryMore like this
J&J’s bispecific combo slashes myeloma progression risk by 89% in phase 3 trial
Fierce Pharmageneral

J&J’s bispecific combo slashes myeloma progression risk by 89% in phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNenJrWHkzSTZpLWpMcENYTkh5UXZKMFM0SVE5LTZMNFlKVUkwbW5na2lsajJzWjhyMEMyeUNZMnZCOFpzNGxDQnhSOGZxQnU5YWstUGFKLVBOZS1EUUVUcHNEYlRjVUY2LUZ4UnNET0RhR01BMTlNQXJ6X2hVZEtuTDVBN1d2eHdmbnBhcHJJMmFrTWV3QnVHTXR5c1ZCUV92NTJRU3c3R04?oc=5" target="_blank">J&J’s bispecific combo slashes myeloma progression risk by 89% in phase 3 trial</a>  <font color="#6f6f6f">Fierce Pharma</font>

Read Full StoryMore like this
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy
Naturegeneral

Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5lVXc1NVBUdFBONk5lOU8tcHpkQ3hBaFFvWU1ZQW9mQkNIbGZ6Zk9ZQWs4SzRzcFJyZ3dmXzBEc3VXdXk2Q0ZzMG13bUhCODJVMTFaT0c2cllxNGFseXhv?oc=5" target="_blank">Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma
CancerNetworkworld

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxObnNXQXlaUjlNVUtBTGYtZ2gxcHJjdnBfV2hKLUYxSG5YQUhrTWJhd1hxMkJ6cE5scGpreXBRTGZWNjNmSU1EZXgtMHR1TDJRTXB4S1hZZ09COEZtLURtVFlFSDVwaUxWSW1MMm9lT0t0UmRCMFdsd0NXUXhQeHExNk1SNHB1MHBKQURYc0JJTXJLUEx5VDFhcDY5aFNfSTB2ZkgycEtB?oc=5" target="_blank">Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Clinical Decision-Making in Multiple Myeloma: Is There a Clear Path for Sequencing Bispecifics and CAR T-Cell Therapy?
ASCO Daily Newsgeneral

Clinical Decision-Making in Multiple Myeloma: Is There a Clear Path for Sequencing Bispecifics and CAR T-Cell Therapy?

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUU16ZUk3Y0hMYkltckN1bGhqdXIyM1JIVXVwbFN5blEtaEJENHVqckVfa3cwZmdTb0JaZVlBWG5oNGJXR0ZqRzhUQkVFYUZOWTZGRmp4SnhvM0tFQlFwTW9EeVhTOFVURXUtN1RMOGVhVmw5b3dTRjluazlRdHZHdHJjZnFCdXZUcWhNdVFFODEzV280SmFPVXZKbTZhUlE0cHRiTDNlbWdERFVrQmozR2U2d2RxVGhxc3E0?oc=5" target="_blank">Clinical Decision-Making in Multiple Myeloma: Is There a Clear Path for Sequencing Bispecifics and CAR T-Cell Therapy?</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?
The Lancetgeneral

Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQZEJ1aS1tcFA1M3cwRXV3N25pMWp6ZHJuZmxmZ05kUmIzUHlQc2RhRmRGc19aZ3JONXk5anJaQUszZWYyVUJDYVdYOWFoZVpoS2RwVk9zNTg0bVNjbXIwT3NuZXpmNDdlclBRem5RTFEwTURDalpRMzU5Qmswc25NWUZneFM4M3JYRk9z?oc=5" target="_blank">Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy
Natureworld

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1NVVNPamdRX2Z5SnFDV0hPRzVqVDNtTFNIVXdhQWxLdWtPVDN3YXg4c1Y0V25pUHhOYzNuZTE4SHNOTFN1YzJqS0VBdXI2N01NcEhFbVptcDlMUFdtR1Vv?oc=5" target="_blank">Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D | Leukemia
Naturegeneral

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D | Leukemia

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE93emdoQXJLbmVudllzWnFJWjNKSllpNlpSZzZreVRld0VIdVlQWHItMkM4ZjRsRUNJRktuQ3A3bEZrWVRNV21mTU16cWF3TVNzMDhjNEtzQ19icFQ2RFcw?oc=5" target="_blank">The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D | Leukemia</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Concurrent CAR T Product Infusion Appears Feasible in R/R Multiple Myeloma
CancerNetworkgeneral

Concurrent CAR T Product Infusion Appears Feasible in R/R Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNM2g0YU9OczktVFZqRGxUX0Vna0NDV1NTdGVpN2Y2dTFpVHF5LW8tcDBtbDl6dHpGMEZOTGo5ekVxYzFwaVdNX0pNQTEwREM4QVE4VXJKa3h0dVRERWZwWUE4akgyTGhtZTloUjd0V1pveTdrUW52cERmSGZEVEs4dkh2eE5wdzFZQlVfTjEwQk5uSTIzX1ZDSFd5ZmxWdnFuMEtHXzdTWXNVMFA5cGc?oc=5" target="_blank">Concurrent CAR T Product Infusion Appears Feasible in R/R Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
Naturegeneral

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5GQVRRZHppUmVJRlhFM2g2a1h5UE14dGZWc2VrQ1VNTVo4RlJ6WTRXcEhFVXZxMFpDUFA2MWdhb2llVUtveGdrQzliXzR3RElYb1lwaUQ2ckRrRGtvMUlN?oc=5" target="_blank">Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Anti-GPRC5D CAR T Cells May Be Viable Multiple Myeloma Salvage Therapy
CancerNetworkgeneral

Anti-GPRC5D CAR T Cells May Be Viable Multiple Myeloma Salvage Therapy

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeXRTcnFJTmd6cFFneWRudXhQUHRvMjkzc2lzQ1hsa2VQS0xWYmNXRFRXMnhTTzRXS0lSWmVJVENPZUJvWmpCX01VZUttd3JuOHRqWUpJQ3ZuV1lHUEM1V09hczlTVEphcEFhYlpqTzhFUEQ1aXctNGo4OUZaMW5ZYU1URHdhamRvVWQ1Sk85dURkdElJRjc0dS12dkhQVDFuazk1OHF1Zjc?oc=5" target="_blank">Anti-GPRC5D CAR T Cells May Be Viable Multiple Myeloma Salvage Therapy</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Naturegeneral

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9HVmM3dzdBMFNyTlZPdFZMLUtHNUpKaDVEM3JRRTlMeUpBTjV6alZ3UnJvMmJzZXo1NFpVbElaWHF4WUJELU11WnJtOFRvRVp5NXdTQVVJaVJBV3N1b1ZJ?oc=5" target="_blank">Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody
Naturegeneral

Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBGMmNLejNGWkdwakF1T2NXdGdFd0ZyZ2VTamFfMmJ5WWtRRVFIZFFOZm82WFhRR1l5WEJwUmk0VUlnaHJENHJBam5qOTdkT1RlS0dwMHFyaTBLTUdQQi1R?oc=5" target="_blank">Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Frontiersgeneral

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQVVRkcFZJRUVZazNNcENWSVdOQ2ZRMzFxOU9Vam01UkMzYUlLSVRjV1Z2bHFhTk9jMFlkQld2WjIwMC04VEkyeUQwcFctREljMU96cHpmSUQyQ1hUWS1uVmh3dEVfZ0owS1cxZnY4WkxOZTVuY3hpT3hTb1pFV3VwUHFGQ1pqUnFsLTlaaWRn?oc=5" target="_blank">Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Sequential CAR T-cell therapy in myeloma: going from BCMA to GPRC5D
The Lancetgeneral

Sequential CAR T-cell therapy in myeloma: going from BCMA to GPRC5D

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOdFg3WExRRlV6N1lhZi1WbzUxLUVDeXNVOUZKMXBrT19pd1daVjVXWmpka0RFbHlDcFRLQWM1S2JyR3N1RlR1cU9tcHV5UHc4UU1KNzRoS05DSHl4eWx1SDdIOGtuRVZFWTJGVWJVbmxtNEFOT3ZVal9aYmdWQVkxZmFtV01PQmtKNGtz?oc=5" target="_blank">Sequential CAR T-cell therapy in myeloma: going from BCMA to GPRC5D</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Science Firsthand: Translating the promise of cell therapy
Bristol Myers Squibbscience

Science Firsthand: Translating the promise of cell therapy

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNV2gzUHZSZDY3ZmtGSmo2NUtiLTFWS2hTeXV2RUdNWEtTODBMU0lBY0tVby1OVFBoMWF3LWV5MVdvaEhzU184YlNNT2FVMEhEMGlMY05MYzlrbW1uX29VS3Q0WjA2ZjgyTzZXNVpKbXNGUHVteHBaM1hhVGN2YmltcnRJY2Zsems?oc=5" target="_blank">Science Firsthand: Translating the promise of cell therapy</a>  <font color="#6f6f6f">Bristol Myers Squibb</font>

Read Full StoryMore like this
GPRC5D-Targeted CAR T Cells for Myeloma
NEJMgeneral

GPRC5D-Targeted CAR T Cells for Myeloma

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9reW9Bc1lQbmc4UGpRRzNOZG1UQkJiUjhRcy05YWJaSF90dm1DS1Ffb0E3RjZicC1ybVk2dEpQN1N1VmhpYUJHUnY2XzVIcTVnLUlwNV8xVDlGcFFjamhFVQ?oc=5" target="_blank">GPRC5D-Targeted CAR T Cells for Myeloma</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma
Roswell Park Comprehensive Cancer Centergeneral

Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOVDhya2t0MWFGeFZZRmRCLWlMZmQxTmRKRU1ibmtJSUVabl9hRFhrWWxmelpfX2ZJVXlpU2R5eVY5QWNQNzAycTdrUDRTczY2dWw0a1doXzI1bksyeDdFeC1FaFNsQk1PVVVjWV8wVkdRbW1zLU0xMlJHbXR2alctMV9IQUVPLTVDMDlmZWJxZVhZLWp5Njg4NUZwb2lyQ3F2SF9xMnRvREZIRlZDNTQwNy1FSWcwOEZzaUhoUHEzcS15VUlHQTdpVA?oc=5" target="_blank">Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma</a>  <font color="#6f6f6f">Roswell Park Comprehensive Cancer Center</font>

Read Full StoryMore like this
Sequencing Bispecific Antibodies and CAR T-Cell Therapy in Multiple Myeloma
ASCO Daily Newsgeneral

Sequencing Bispecific Antibodies and CAR T-Cell Therapy in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZW5GaUQxTTZ6eDczM3haOHJTNW9qRVV0QlB3VkNiRWQ0anFNcHpmaEZmYXdabHNuLWdWbkhaVzhLNldhRVc5akdDZV9MZkhBUGZjRDlRT1hGTGNkbXJvS1BEVnVxc05hZmR3aWVlcjBtZHphXy1OWmF6QUw0dFRtQmo0WFNzVjRNaFdhOXRrcUxpVWhCckdGMFhvdTJNd0VvMV9pWGpmbEUtUQ?oc=5" target="_blank">Sequencing Bispecific Antibodies and CAR T-Cell Therapy in Multiple Myeloma</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
Natureworld

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE04VkRseVZiS2QySXV4cFc1MGNES1dPVm5uTFFscEpwaHNVZUtZU2pZQ3lPMXc0OWJWUHZkbHRva29ycXFscGJJOVRuTUR6NUVYQkFHalVFcUF6dkpiMVlN?oc=5" target="_blank">Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients
Frontierstech

Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOZmFGWFlBUnJxVmJuOHMzNXF4N1pFdm1UQ2tOenoxaGMyaTJrc0t3ajltZHV2a1R6akZZd1lnYmVZTnJWemt1eWx2clMzM0poTndUYkYzN0UtQ2tWbDEwUTJ4bkc5dFZncXBqQkJlRF9obkFiSzJORi1OTzRFY2VYUGxlVUpWenlWX2xJaUZ6QU1YMlAw?oc=5" target="_blank">Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Strategic Use of BCMA- and GPRC5D-Directed Bispecifics in R/R MM
OncLivegeneral

Strategic Use of BCMA- and GPRC5D-Directed Bispecifics in R/R MM

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQZ3duV1FDX1V1YmVQN0lGa09YTkZwMmQ3dW9SUHM1MTRrZVhVMGo1VGxjZFR4TnlfeDBTUDgtMnJ2bW1aTWxwd3ZzT3FGUHhxajQ5S3VoMVFqV0Q4S2NEM2FoVUQ1X2JGZV81am9UUVBpSDA5RjVPOUtSd0dxVkpGaW1MNTNQeHBsWExtYmo3MG40U3VtMERKVQ?oc=5" target="_blank">Strategic Use of BCMA- and GPRC5D-Directed Bispecifics in R/R MM</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma
CancerNetworkgeneral

Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNRGFxaEhFS0VJQVNBUmdVVFpFZk41cVFJeXUwTzBIY3Zqdi1GUFFSaHJBVXhJNzhsM3ZKNWRSVzllZHhoYUo0d3c4REZEUEZTYkdhWG9yVjdoMDgxdXA3VTdTMkFZT2tJbm1YUEVoTWljd1hRcUlHYlN4VE1ZUjZIT0VPcmFtYWYzQ2d4cnNnMmgxWG5uVlZvSlBmMnI1ZmQ1Y05rX2N2Mi1rNlg3?oc=5" target="_blank">Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
"BCMA/GPRC5D CAR T-Cell Th" — Live Google News Trends & Headlines